CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: December 8, 2020
Result type: Reports
Project Number: SR0648-000
Product Line: Reimbursement Review

Generic Name: etonogestrel

Brand Name: Nexplanon

Manufacturer: Merck Canada Inc.

Therapeutic Area: Prevention of pregnancy

Indications: Indicated for the prevention of pregnancy for up to 3 years

Manufacturer Requested Reimbursement Criteria1: Indicated for the prevention of pregnancy for up to 3 years

Submission Type: Initial

NOC Status at Filing: Post NOC

Project Status: Complete

Companion Diagnostics: No

Date Recommendation Issued: October 20, 2020

Recommendation Type: Reimburse with clinical criteria and/or conditions

Fee Schedule: Schedule A

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openMay 06, 2020
Call for patient input closedJune 25, 2020

- No patient input submission received

Submission receivedJune 03, 2020

Submission was previously withdrawn and has been refiled by the sponsor

Submission acceptedJune 17, 2020
Review initiatedJune 18, 2020
Draft CADTH review report(s) provided to sponsor for commentJuly 31, 2020
Deadline for sponsors commentsAugust 12, 2020
CADTH responses on draft review report(s) provided to sponsorSeptember 03, 2020
Expert committee meeting (initial)September 16, 2020
Draft recommendation issued to sponsorSeptember 28, 2020
End of embargo periodOctober 13, 2020
Final recommendation issued to sponsor and drug plansOctober 20, 2020
Final recommendation postedOctober 22, 2020
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)November 03, 2020
CADTH review report(s) postedDecember 07, 2020